Atrium Therapeutics Inc (RNA)

Jun 08, 2026

Atrium Therapeutics, Inc. (RNA) Stock Analysis: Unveiling a 111.86% Potential Upside in the Biotech Arena - DirectorsTalk Interviews

Jun 08, 2026

Jun 06, 2026

Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: Narrower Loss Beats Estimates Amid Pipeline Progress - newsline.com

Jun 06, 2026

Jun 05, 2026

Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: EPS Beats Estimates Despite Pre-Revenue Status; Stock Drops on Cash Burn ConcernsEPS Miss Report - newsline.com

Jun 05, 2026

Jun 05, 2026

Atrium Therapeutics (RNA) Slips 2.28% as Biotech Sector Faces HeadwindsPCR Moving Average - newsline.com

Jun 05, 2026

Jun 01, 2026

Atrium Therapeutics, Inc. (RNA) - DirectorsTalk Interviews

Jun 01, 2026

Jun 01, 2026

Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Operational DisciplineBuyback Announcement Report - newsline.com

Jun 01, 2026

May 30, 2026

RNA Price Today: Atrium Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC

May 30, 2026

May 28, 2026

Here's Why We're Not Too Worried About Atrium Therapeutics' (NASDAQ:RNA) Cash Burn Situation - Yahoo Finance

May 28, 2026

May 26, 2026

Atrium Therapeutics Inc. (RNA) Holds Steady Near Resistance as Momentum BuildsCash Flow Strong Stocks - newsline.com

May 26, 2026

May 25, 2026

Atrium Therapeutics, Inc. (RNA) Stock Analysis: Exploring a 90.99% Potential Upside in RNA Therapeutics - DirectorsTalk Interviews

May 25, 2026

May 23, 2026

Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Investor Sentiment - Newser

May 23, 2026

May 21, 2026

Atrium Therapeutics (RNA) Stages a Recovery: Testing Key Resistance at $13.69Crowd Stock Picks - Newser

May 21, 2026

May 20, 2026

Atrium Therapeutics Inc - Reuters

May 20, 2026

May 16, 2026

RNA Initiated Coverage by Leerink Partners -- Rating Set to Outp - GuruFocus

May 16, 2026

May 15, 2026

RA Capital (RNA) healthcare fund discloses 864,102 shares, 5.6% stake - Stock Titan

May 15, 2026

May 15, 2026

Leerink initiates Atrium Therapeutics stock with outperform rating By Investing.com - Investing.com Canada

May 15, 2026

May 15, 2026

Leerink Partners Initiates Atrium Therapeutics(RNA.US) With Buy Rating, Announces Target Price $25 - Moomoo

May 15, 2026

May 15, 2026

Leerink Partners Initiates Coverage on Atrium Therapeutics With Outperform Rating, $25 PT - Moomoo

May 15, 2026

May 15, 2026

Atrium Therapeutics 1Q Loss/Shr 97c >RNA - Moomoo

May 15, 2026

May 14, 2026

Atrium Therapeutics Reports First Quarter 2026 Financial Results - Investing News Network

May 14, 2026

May 14, 2026

Atrium Therapeutics 1Q Rev $19.6M >RNA - Moomoo

May 14, 2026

May 14, 2026

Atrium Therapeutics Believes Cash Resources Sufficient to Fund Planned Ops Through Key Clinical Proof-Of-Concept Milestones >RNA - Moomoo

May 14, 2026

May 14, 2026

Atrium Therapeutics (RNA) Q1 2026: milestone revenue, higher R&D and $267.8M cash - Stock Titan

May 14, 2026

May 14, 2026

Atrium Therapeutics Reports Q1 2026 Financial Results and Corporate Progress - Intellectia AI

May 14, 2026

May 14, 2026

Atrium Therapeutics reports Q1 2026: $19.6M collaboration revenue, $267.8M cash - TradingView

May 14, 2026

May 14, 2026

Atrium Therapeutics, Inc. 1Q 2026: Revenue $19.6M, EPS $(0.97) — 10-Q Summary - TradingView

May 14, 2026

May 14, 2026

Atrium Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 14, 2026

May 14, 2026

Atrium Therapeutics Q1 collaboration revenue surges after spin-off - TradingView

May 14, 2026

May 14, 2026

Atrium Therapeutics (Nasdaq: RNA) Q1 2026 results show higher revenue and loss - Stock Titan

May 14, 2026

May 12, 2026

Fierce Biotech Fundraising Tracker '26: Create corrals $122M; Isomorphic's $2B series B - Fierce Biotech

May 12, 2026

May 11, 2026

Atrium Therapeutics, Inc. (RNA) Stock Analysis: Exploring the 91% Potential Upside in RNA Therapeutics - DirectorsTalk Interviews

May 11, 2026

May 08, 2026

RNA (Atrium Therapeutics) revenue surges 70.8% in Q1, but shares slip as losses persist.Investment Community Signals - newser.com

May 08, 2026

May 08, 2026

How Atrium Therapeutics (RNA) performance compares to expectations (Underperforming) 2026-05-08Earnings Miss Risk - Newser

May 08, 2026

May 06, 2026

What Atrium Therapeutics (RNA) is doing to earn customer loyalty (Nudges Up) 2026-05-06Index Investing - newser.com

May 06, 2026

May 04, 2026

Atrium Therapeutics, Inc. (RNA) Stock Analysis: Exploring an 86% Potential Upside in RNA Therapeutics - DirectorsTalk Interviews

May 04, 2026

May 03, 2026

RNA 260618 33.00P (RNA260618P33000) Stock Options Chain | Quotes & News - Moomoo

May 03, 2026

Apr 28, 2026

Atrium Therapeutics (RNA) price target decreased by 65.57% to 25.50 - MSN

Apr 28, 2026

Apr 27, 2026

BlackRock (NASDAQ: RNA) reports 5.2% stake — 892,387 shares - Stock Titan

Apr 27, 2026

Apr 24, 2026

Milestone in Atrium and BMS cardiovascular collaboration - BioWorld News

Apr 24, 2026

Apr 23, 2026

BMY Secures $15M Milestone Payment to Atrium Therapeutics - GuruFocus

Apr 23, 2026

Apr 23, 2026

Atrium Therapeutics earns $15M from Bristol Myers Squibb By Investing.com - Investing.com South Africa

Apr 23, 2026

Apr 23, 2026

Atrium Therapeutics earns $15M from Bristol Myers Squibb - Investing.com

Apr 23, 2026

Apr 23, 2026

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration - PR Newswire

Apr 23, 2026

Apr 23, 2026

RNA SEC FilingsAtrium Therapeutics, Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 23, 2026

Apr 23, 2026

RNA (Atrium Therapeutics Inc.) posts 70.8 percent year over year Q1 2026 revenue growth, shares rise 3.71 percent. - Xã Thanh Hà

Apr 23, 2026